NKGen Biotech, Inc.
OTC: NKGN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul Y. Song
- Employees
- 26
- Headquarters
- Santa Ana, United States
- IPO year
- 2021
- Market cap
- $7.8M
- Website
- https://nkgenbiotech.com
Loading NKGN…
Loading profile data…Frequently asked questions about NKGN
What does NKGen Biotech, Inc. (NKGN) do?
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative d...
Where does NKGN trade?
NKGen Biotech, Inc. (NKGN) trades on the Other OTC.
What sector is NKGN in?
NKGen Biotech, Inc. (NKGN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NKGen Biotech, Inc.?
Paul Y. Song is the chief executive officer of NKGen Biotech, Inc. (NKGN).
Where is NKGen Biotech, Inc. headquartered?
NKGen Biotech, Inc. is headquartered in United States.
Does NKGN pay a dividend?
NKGen Biotech, Inc. (NKGN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NKGN go public?
NKGen Biotech, Inc. (NKGN) completed its initial public offering in 2021.